A severe winter storm has necessitated postponement of Gateway Analytical's grand opening ceremony from February 1 to April 12. Gateway is a subsidiary of ChemImage and offers particle analysis services including ingredient-specific particle sizing for MDIs and nasal sprays. Read the company's press release. … [Read more...] about Gateway Analytical grand opening postponed due to weather
Business
Allergan to co-promote Levadex with MAP
Assuming that MAP Pharmaceuticals' Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care physicians in the United States and will retain all rights outside the US. MAP plans to submit an NDA for Levadex by the … [Read more...] about Allergan to co-promote Levadex with MAP
CyDex acquired by Ligand Pharmaceuticals
California-based biotech company Ligand Pharmaceuticals has acquired CyDex Pharmaceuticals and its Captisol solubility-enhancing technology. CyDex's pipeline includes a Captisol-enhanced budesonide/azelastine nasal spray. Ligand will operate CyDex as a wholly-owned subsidiary. Read the company's press release. … [Read more...] about CyDex acquired by Ligand Pharmaceuticals
Dutch court rules against GSK in Advair patent case
A court in The Hague has ruled in favor of Sandoz and Hexal, both units of Novartis, agreeing that the Dutch portion of GSK's European patent for Advair is not valid. GSK may appeal the ruling. Read a Reuters article. … [Read more...] about Dutch court rules against GSK in Advair patent case
Alexza says it will resubmit AZ-004 NDA in July 2011
According to Alexza Pharmaceuticals, it plans to resubmit its NDA for AZ-004 (Staccato loxapine) for the treatment of agitation in schizophrenic patients in July 2011. The company received a complete response letter (CRL) for the product from the FDA in October 2010. The FDA CRL cited safety concerns due to decreases in FEV1 after inhalation of a dose. Read the … [Read more...] about Alexza says it will resubmit AZ-004 NDA in July 2011
Indian company gets patent for anti-emetic nasal spray
According to reports, Lincoln Pharmaceuticals of Ahmedabad, India has been awarded an Indian patent for a nasal formulation of ondansetron hydrochloride intended to prevent nausea and vomiting for chemotherapy patients. The company says that it will begin marketing the product in India within the next few months and intends to market it internationally in the … [Read more...] about Indian company gets patent for anti-emetic nasal spray
Dance and Aerogen developing inhaled insuin product
Aerogen has licensed its OnQ nebulizer technology to a San Francisco, California company, Dance Pharmaceuticals for development of a new inhaled insulin solution product. Dance founder John S. Patton was a co-founder of Inhale Therapeutics, which later became Nektar and developed Exubera inhaled insulin. Read the companies' press release. … [Read more...] about Dance and Aerogen developing inhaled insuin product
Alkermes pulmonary delivery spin-out Civitas gets $20 million
Civitas Therapeutics has obtained $20 million in Series A financing for development of its lead product, a DPI intended for the treatment of Parkinson's disease. The assets Civitas has licensed from Alkermes include a pipeline, delivery technology, and a manufacturing facility. Management of the new company includes Glenn Batchelder, CEO; Richard Batycky, Chief … [Read more...] about Alkermes pulmonary delivery spin-out Civitas gets $20 million
Ritedose recalls albuterol inhalation solution vials in US
Contract manufacturer Ritedose has voluntarily recalled unit dose vials of albuterol inhalation solution due to mislabeling. The single dose vials contain a 2.5 mg/3 mL solution but are labeled as 0.5 mg/3 mL. The product was distributed across the United States and in Puerto Rico. Read the company's press release. … [Read more...] about Ritedose recalls albuterol inhalation solution vials in US
Intranasal insulin company CPEX acquired
A subsidiary of Footstar has entered into an agreement to acquire New Hampshire specialty pharma company CPEX, which is developing Nasulin intranasal insulin spray. Nasulin is in Phase 2 development, and CPEX has been seeking to license the product or to sell the program outright. Read the company's press release. … [Read more...] about Intranasal insulin company CPEX acquired